Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27221
IPSCIO Record ID: 28235
INOpulse is based on the Companyâ€™s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.
The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patientâ€™s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patientâ€™s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.
IPSCIO Record ID: 857
The Channel Agreement grants the Licensee a worldwide License to use specified patents and other intellectual property of the Licensor in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving the production of PGIS (prostacylin synthase) through the use of an in vivo conditionally regulated embedded controllable bioreactor for the treatment of Pulmonary arterial hypertension (PAH) in humans.
Licensee may not subLicense the rights described without Licensor's written consent.
The synthetic biologic product candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed to deliver DNA that encodes a therapeutic protein called prostacyclin synthase (PGIS) locally to the pulmonary arteries of PAH patients via a single procedure, and, via an oral daily pill, control the long-term local expression of such therapeutic protein.
Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries of your lungs. Itâ€™s a serious condition that can make it difficult for blood to flow through your lungs. This can force your heart to work harder than normal.
The Licensee intends to use the Licensor's technology directed towards the production of PGIS, through the use of in vivo conditionally regulated embedded controllable bioreactors for the treatment of PAH.
IPSCIO Record ID: 230780
'Existing Patents' means the RSD930 and RSD1236 Patent Families (ApplicationNumbers US 09/328,540; PCT/CA99/00535; US 09/328,541; PCT/CA99/00534; PCT/CA00/01506; PCT/CA00/01507; PCT/CA00/01508; PCT/CA98/00842 and Thailand Patent Appl.# 045858; Taiwan Patent Appl.# 87114395; The Philippines Patent Appl. # 98/2246; and Malaysia Patent Appl. # Pl 9804017 and all patentm applications claiming priority therefrom or sharing at least one common priority therewith).
IPSCIO Record ID: 4994
IPSCIO Record ID: 49323
IPSCIO Record ID: 28029
Compound shall mean the bulk active pharmaceutical ingredient tadalafil.
Pulmonary Arterial Hypertension or PAH shall mean all WHO classifications of pulmonary arterial hypertension identified in the Venice 2003 Revised Classification system.
Protocol H6D-MC-LVGX(f) An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension.
5,859,006, Granted January, 12, 1999
6,821,975, Granted November 23, 2004
7, 182, 958, Granted February 27, 2007
US Application 10/521,393
IPSCIO Record ID: 194318
U.S. Patent Nos. 6,821,975 (expiring November 19, 2020) (â€œ975â€) and 7,182,958 (expiring April 26, 2020) (â€œ958â€)